1.Management consideration in nonpulmonary visceral metastatic seminoma of testis.
Dong Soo PARK ; Debra M PROW ; Robert J AMATO ; Christopher J LOGOTHETIS
Journal of Korean Medical Science 1999;14(4):431-437
To develop a more appropriate therapeutic strategy for treatment of nonpulmonary visceral metastatic testicular seminoma based on the International Germ Cell Consensus Classification, we reviewed the medical records of patients with nonpulmonary visceral metastatic testicular seminoma who were treated over a 20-year period. Only 15 (2.2%) of the 686 cases of testicular seminoma were nonpulmonary visceral metastatic seminoma. The median age of patients was 38 years (range, 22-53 years). Ten (67%) of the patients had an initial diagnosis of supradiaphragmatic or visceral metastatic disease. In addition to nonpulmonary visceral metastasis, all patients had lymph node metastasis as well, the majority of which involved the retroperitoneal lymph nodes. The median and mean progression-free survival durations after chemotherapy for advanced disease were 19 months and 63.7 months, respectively. Six patients (40%) survived, five relapsed after radiation therapy and four died of chemorefractory disease not dependent on the specific regimen. Although the number of cases reviewed in this study was small, we conclude that the choice of chemotherapeutic regimen among the current treatments for nonpulmonary visceral metastatic seminoma of testis primary does not present a different outcome. Therefore, multimodality therapies using new strategies or new agents are well indicated.
Adult
;
Antineoplastic Agents, Combined/administration & dosage*
;
Bone Neoplasms/secondary
;
Bone Neoplasms/radiotherapy
;
Bone Neoplasms/drug therapy
;
Combined Modality Therapy
;
Human
;
Lung Neoplasms/secondary
;
Lung Neoplasms/radiotherapy
;
Lung Neoplasms/drug therapy
;
Lymphatic Metastasis
;
Male
;
Middle Age
;
Retroperitoneal Neoplasms/secondary*
;
Retroperitoneal Neoplasms/radiotherapy
;
Retroperitoneal Neoplasms/drug therapy*
;
Retrospective Studies
;
Seminoma/secondary*
;
Seminoma/radiotherapy
;
Seminoma/drug therapy*
;
Testicular Neoplasms/pathology*
2.A Case of Benign Metastasizing Leiomyoma with Multiple Metastasis to the Soft Tissue, Skeletal Muscle, Lung and Breast.
Ji Hoon JO ; Jin Hwa LEE ; Dae Cheol KIM ; Sung Hyun KIM ; Hyuk Chan KWON ; Jae Seok KIM ; Hyo Jin KIM
The Korean Journal of Internal Medicine 2006;21(3):199-201
Benign metastasizing leiomyoma (BML) is composed of well-differentiated smooth muscle cells and dense connective tissue. BML affects middle-aged women who have had previous hysterectomies due to a histologically benign-appearing uterine leiomyoma. We report here on a case of BML from the uterine leiomyoma in a 39-year-old woman that involved the soft tissues, skeletal muscles, lungs and breasts. She underwent a hysterectomy for the uterine leiomyoma, double oophorectomy for hormonal ablation and lung wedge resection to confirm the diagnosis. The microscopic findings of the breast and lung tumor were similar to those of the benign uterine leiomyoma. Therefore, we consider that these lesions were breast and pulmonary metastases of the uterine leiomyoma. We report here on a rare case of benign metastasizing uterine leiomyoma that involved the soft tissue, skeletal muscles, lungs and breasts, and we include a review of the relevant literature.
Uterine Neoplasms/*pathology/surgery
;
Tamoxifen/therapeutic use
;
Soft Tissue Neoplasms/*secondary
;
Muscle, Skeletal/pathology
;
Muscle Neoplasms/*secondary
;
Lung Neoplasms/*secondary
;
Leiomyoma/drug therapy/*pathology
;
Hysterectomy
;
Humans
;
Female
;
Breast Neoplasms/*secondary
;
Antineoplastic Agents/therapeutic use
;
Adult
3.Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases.
Yon Ju RYU ; Eun Mi CHUN ; Soon Nam LEE ; Sung Shin SHIM
Korean Journal of Radiology 2014;15(2):300-304
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib associated with pulmonary cystic changes has not been reported yet. In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy.
Antineoplastic Agents/*adverse effects
;
Brain Neoplasms/secondary
;
Carcinoma, Non-Small-Cell Lung/*drug therapy/secondary
;
Cysts/*chemically induced
;
Female
;
Humans
;
Lung/pathology
;
Lung Diseases/*chemically induced
;
Lung Diseases, Interstitial
;
Lung Neoplasms/*drug therapy
;
Middle Aged
;
Quinazolines/*adverse effects
4.Micropapillary Lung Cancer with Breast Metastasis Simulating Primary Breast Cancer due to Architectural Distortion on Images.
Kyungran KO ; Jae Yoon RO ; Eun Kyung HONG ; Seeyeon LEE
Korean Journal of Radiology 2012;13(2):249-253
A 47-year-old Korean woman with right middle lobe lung adenocarcinoma, malignant pleural effusion, and multiple lymph node and bone metastases, after three months of lung cancer diagnosis, presented with a palpable right breast mass. Images of the right breast demonstrated architectural distortion that strongly suggested primary breast cancer. Breast biopsy revealed metastatic lung cancer with a negative result for estrogen receptor (ER), progesterone receptor (PR) and mammaglobin, and a positive result for thyroid transcription factor-1 (TTF-1). We present a case of breast metastasis from a case of lung cancer with an extensive micropapillary component, which was initially misinterpreted as a primary breast cancer due to unusual image findings with architectural distortion.
Adenocarcinoma/drug therapy/*secondary
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Biopsy, Needle
;
Bone Neoplasms/secondary
;
Breast Neoplasms/drug therapy/*secondary
;
Diagnosis, Differential
;
Female
;
Humans
;
Lung Neoplasms/*pathology
;
Lymphatic Metastasis
;
Mammography
;
Middle Aged
;
Neoplasm Staging
;
Tomography, X-Ray Computed
;
Ultrasonography, Mammary
5.Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer.
Jin-hai TANG ; Jian-hua ZHAO ; Jian-ping GONG ; Jian-wei QIN ; Li-qun PAN ; Zhi-yin XU
Chinese Journal of Oncology 2007;29(3):210-214
OBJECTIVETo study the changes in circulating VEGF and endostatin (ES) levels during chemotherapy for patients with breast cancer, and their correlation with efficacy of chemotherapy.
METHODS40 breast cancer patients with metastases were included in this study. They received TAC/TEC, CAF/CEF, NP, CAP, CMF, TFP, TA or TC regime chemotherapy, respectively. Totally 120 serum samples were collected from the patients at three time points: before chemotherapy, the end of 1 and 5-6 chemotherapy cycles, and analyzed for VEGF and ES levels using ELISA. Tumor agiogenesis activity was evaluated by serum soluble vascular cell adhesion molecule (VCAM - 1) measured by ELISA as a surrogate marker.
RESULTS(1) Before chemotherapy, the median level of VEGF in patients with breast cancer was 496.6 pg/ml, 4.7 times higher than that of healthy controls (P <0.001). The median level of ES was 95.5 ng/ml, 18.3% lower than that of healthy controls (P = 0.183). VCAM-1 was 1077.1 ng/ml and higher than that of controls (P <0.001). The serum VEGF levels correlated with VCAM-1 levels, tumor staging and metastatic sites (P <0.05). (2) At the end of 1 cycle of chemotherapy, the serum VEGF level (median 524.8 pg/ml) was higher than the pretreatment values (P = 0.047), whereas the levels of ES and VCAM-1 were not significantly altered (110.5 ng/ml, P = 0.055; and 975.6 ng/ml, P = 0.27). (3) At the end of 5-6 cycles, the changes in VEGF correlated with the response to chemotherapy. Serum VEGF levels in 27 patients with chemotherapy-responsive and stable disease showed a significant decrease (median 287.4 pg/ml) , but not observed in 13 patients with progressive disease. VCAM-1 also showed a treatment-related change like VEGF. However, chemotherapy might only have a minor effect on ES, because there was no significant difference in the ES levels among 5-6 cycle patients, 1 cycle patients and healthy controls, and neither between therapy-responsive patients.
CONCLUSIONIntensive chemotherapy for breast cancer results in a significant decrease of serum VEGF level, which might be an indicator of the controlled disease status, and following the treatment-induced response or stabilization, the tumor angiogenesis seems to change into an anti-angiogenesis direction.
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Bone Neoplasms ; blood ; drug therapy ; secondary ; Breast Neoplasms ; blood ; drug therapy ; pathology ; Carcinoma, Ductal, Breast ; blood ; drug therapy ; secondary ; Endostatins ; blood ; Female ; Humans ; Liver Neoplasms ; blood ; drug therapy ; secondary ; Lung Neoplasms ; blood ; drug therapy ; secondary ; Lymphatic Metastasis ; Middle Aged ; Neoplasm Staging ; Remission Induction ; Vascular Cell Adhesion Molecule-1 ; blood ; Vascular Endothelial Growth Factor A ; blood
6.Low-grade extraskeletal osteosarcoma of mediastinum: report of a case.
Hong YU ; Chao-fu WANG ; Xiong-zeng ZHU
Chinese Journal of Pathology 2012;41(11):770-771
Adult
;
Chemotherapy, Adjuvant
;
Diagnosis, Differential
;
Female
;
Humans
;
Lung Neoplasms
;
secondary
;
Mediastinal Neoplasms
;
diagnostic imaging
;
drug therapy
;
pathology
;
surgery
;
Mediastinum
;
diagnostic imaging
;
pathology
;
Neoplasm Recurrence, Local
;
Osteosarcoma
;
diagnostic imaging
;
drug therapy
;
pathology
;
secondary
;
surgery
;
Tomography, X-Ray Computed
7.Short-term effects of chemotherapy with combination of hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers.
Yuan-jue SUN ; Hui ZHAO ; Yue-wu GUO ; Feng LIN ; Xun CAI ; Xiao-chun TANG ; Yang YAO
Chinese Journal of Oncology 2004;26(12):749-752
OBJECTIVETo evaluate the short-term therapeutic effects and side effects of combined hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers.
METHODSThirty patients suffering from advanced digestive tract tumors including gastric cancer 8, colorectal cancer 20, cholecystic cancer 1 and malignant fibroadenoma 1 were studied. They were treated with hydroxycamptothecine plus oxaliplatin for 2 cycles with interval of 21 days.
RESULTSThe complete response, partial response, stable disease and progressive disease rates were 3.3% (1/30), 36.7% (11/30), 53.3% (15/30) and 6.7% (3/30) respectively with an overall response rate (CR + PR) of 40.0% (12/30). In the whole 77 cycles, leukocytopenia was observed in 34 cycles (44.2%) and 19 cycles (55.9%) at grades III and IV. Diarrhea developed in 42 cycles (54.5%) and 20 cycles (47.6%) grades III and IV. The other side effects were fever, alopecia, nausea and vomiting, constipation, hepatic and renal function abnormity and neuritis.
CONCLUSIONSatisfactory response rate is obtainable in advanced colorectal cancer as treated by hydroxycamptothecine plus oxaliplatin. The toxicity consists of severe leukocytopenia and diarrhea.
Adenocarcinoma ; drug therapy ; secondary ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Camptothecin ; administration & dosage ; analogs & derivatives ; Colorectal Neoplasms ; drug therapy ; pathology ; Diarrhea ; chemically induced ; Female ; Humans ; Leukopenia ; chemically induced ; Liver Neoplasms ; drug therapy ; secondary ; Lung Neoplasms ; drug therapy ; secondary ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds ; administration & dosage ; Remission Induction ; Stomach Neoplasms ; drug therapy ; pathology ; Treatment Outcome
8.Antimetastatic effects of genistein on salivary adenoid cystic carcinoma in vivo.
Chinese Journal of Stomatology 2004;39(5):373-375
OBJECTIVETo study the antimetastatic effects of genistein on salivary adenoid cystic carcinoma (ACC-M) in vivo.
METHODSACC-M cells were exposed to genistein for 3 days. The treated cells and control cells were then injected into the tail vein of 20 nude mice, which were randomized into 2 groups. The mice were sacrificed at the sixth week after implantation. The lung metastasis rates and the number of metastases were detected. Apoptosis index (AI), the expression of VEGF and MMP-9 of the lung metastases were also observed.
RESULTSCompared to the control groups, the number of metastases was significantly reduced in genistein treated group (P < 0.05). The AI of ACC-M cells was higher in the treated group than in the control group (P < 0.05). The level of VEGF and MMP-9 expression were decreased in the treated groups (P < 0.05).
CONCLUSIONSGenistein has a moderate inhibitory effect on metastasis of ACC. Inducing apoptosis, inhibiting the expression of VEGF and MMP-9 are the mechanisms of antimetastatic effects of genistein on ACC-M in nude mice.
Animals ; Antineoplastic Agents ; administration & dosage ; Carcinoma, Adenoid Cystic ; drug therapy ; secondary ; Female ; Genistein ; administration & dosage ; Lung Neoplasms ; drug therapy ; secondary ; Mice ; Mice, Nude ; Random Allocation ; Salivary Gland Neoplasms ; drug therapy ; pathology
9.Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma.
Yan SONG ; Jing HUANG ; Jin-Wan WANG
Chinese Journal of Cancer 2010;29(1):76-81
BACKGROUND AND OBJECTIVEThere is a mounting evidence of the role of HER2 overexpression inpatients with gastric cancer, and it has been solidly correlated with poor outcomes and more aggressive diseases. This study was to investigate the relationship between the expression of HER2/neu and the clinical characteristics of advanced gastric carcinomas, including survival.
METHODSThe clinical data of 83 patients admitted in Cancer Hospital, Chinese Academy of Science, from 2006 to 2008 were reviewed. The HER2/neu status in 83 advanced gastric carcinomas was evaluated using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The survival rate was calculated by Kaplan-Meier method and the log-rank test using SPSS13.0 software.
RESULTSThe median age of the patients was 60 years and the male-to-female ratio was 2.95:1. HER2/neu overexpression (2+ and 3+) and amplification were found in 25 (30.1%) and 29 (34.9%) advanced gastric carcinomas, respectively. HER2/neu amplification/overexpression was associated with worse survival in patients with advanced gastric carcinoma. The median survival of the patients without HER2/neu amplification was 12.6 months and that of those with HER2 amplification was 5.5 months.
CONCLUSIONSHER2/neu status may be a clinical predictor of prognosis in advanced gastric cancer patients.
Adenocarcinoma ; drug therapy ; genetics ; metabolism ; pathology ; secondary ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Carcinoma, Signet Ring Cell ; drug therapy ; genetics ; metabolism ; pathology ; secondary ; Female ; Gene Amplification ; Gene Expression Regulation, Neoplastic ; Genes, erbB-2 ; Humans ; Liver Neoplasms ; secondary ; Lung Neoplasms ; secondary ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Receptor, ErbB-2 ; metabolism ; Stomach Neoplasms ; drug therapy ; genetics ; metabolism ; pathology ; Survival Rate
10.Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer.
Tao WANG ; Ze-fei JIANG ; San-tai SONG ; Shao-hua ZHANG ; Ge SHEN ; Jing-xin YU
Chinese Journal of Oncology 2004;26(6):379-381
OBJECTIVETo evaluate the efficacy and adverse reactions of Xeloda in the treatment of recurrent and metastatic breast cancer.
METHODSThis clinical study was designed to treat 69 patients with recurrent and metastatic breast cancer with Xeloda, 2500 mg/m(2)/d, twice daily for 2 weeks followed by a 1-week rest period, repeated every 3 weeks.
RESULTSSixty-nine patients received Xeloda for more than 1 cycle. The overall response rate (CR + PR) was 16.0%, clinical benefit rate (CR + PR + SD > or = 24 months) was 27.5%, disease control rate (CR + PR + SD) was 75.4%. The median time to failure (TTF) was 3 months (range: 0.7 - 11 months). The median time to progression (TTP) was 2 months (range: 0.7 - 11 months). The median duration of response (CR + PR) was 6 months (range: 4 - 11 months). The most common treatment-related adverse events were hand-foot syndrome (HFS) that occurred in 60.8% (42/69) patients mostly as grade I-II. Fifty-five percent (22/40) of patients who had received high dose preventive Vit B6 developed HFS without grade III; while 69% (20/29) of patients who had not received such treatment did develop HFS including 2 patients with grade III. However, there was not significant difference between the two groups.
CONCLUSIONXeloda is an effective and well tolerated treatment in patients with recurrent and metastatic breast cancer. The symptoms of HFS may be relieved by high dose Vit B6 as prevention.
Adult ; Aged ; Antimetabolites, Antineoplastic ; therapeutic use ; Bone Neoplasms ; drug therapy ; secondary ; Breast Neoplasms ; drug therapy ; pathology ; Capecitabine ; Deoxycytidine ; analogs & derivatives ; therapeutic use ; Drug Administration Schedule ; Female ; Fluorouracil ; analogs & derivatives ; Humans ; Liver Neoplasms ; drug therapy ; secondary ; Lung Neoplasms ; drug therapy ; secondary ; Lymphatic Metastasis ; Middle Aged ; Neoplasm Recurrence, Local ; drug therapy